Workflow
医药电商
icon
Search documents
华人健康跌1.01%,成交额4249.06万元,后市是否有机会?
Xin Lang Cai Jing· 2025-09-26 08:06
Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is actively expanding its presence in the health sector, particularly focusing on elderly care and innovative pharmaceutical products, while facing fluctuations in stock performance and market interest [2][3][8]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and listed on March 1, 2023. The company primarily engages in pharmaceutical agency, retail, and terminal procurement, with its main revenue derived from traditional Chinese and Western medicine, accounting for 97.60% of total revenue [7]. - The company is located in Hefei, Anhui Province, and operates within the pharmaceutical and biological industry, specifically in the pharmaceutical commercial sector, focusing on offline pharmacies [7]. Business Strategy - The company is strategically positioning itself in the silver-haired health sector by providing chronic disease training and services through pharmacies, aiming to enhance health management for the elderly [2]. - It is developing a series of products targeting common diseases among the elderly, including the "Fuman Medical" series for cardiovascular health and the "Guojin" series of traditional Chinese medicine for health maintenance [2][3]. Financial Performance - For the first half of 2025, the company reported a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%, and a net profit attributable to shareholders of 104 million yuan, up 42.17% from the previous year [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [8]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 45.15% to 26,100, with an average of 5,725 shares held per person, a decrease of 31.10% [8]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company, and there are collaborations with various Alibaba platforms [3][8]. Market Activity - On September 26, the company's stock price fell by 1.01%, with a trading volume of 42.49 million yuan and a market capitalization of 5.08 billion yuan [1]. - The stock has shown no clear trend in major net inflows, with a net outflow of 8.27 million yuan on the day [4][5].
九芝堂涨2.12%,成交额1.11亿元,主力资金净流入59.34万元
Xin Lang Cai Jing· 2025-09-26 03:29
Company Overview - JiuZhiTang has seen a stock price increase of 32.19% year-to-date, but has experienced a slight decline of 0.30% over the last 5 trading days and a more significant drop of 11.53% over the last 20 days [2] - The company specializes in the research, production, and sales of traditional Chinese medicine, biological pharmaceuticals, and cardiovascular drugs, with its main revenue sources being prescription drugs (50.27%) and OTC products (46.11%) [2] Financial Performance - For the first half of 2025, JiuZhiTang reported a revenue of 1.265 billion yuan, representing a year-on-year decrease of 24.71%, while the net profit attributable to shareholders was 144 million yuan, down 29.71% year-on-year [3] - Cumulative cash dividends since the company's A-share listing amount to 4.364 billion yuan, with 935 million yuan distributed over the past three years [4] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 50,500, marking a 25.14% rise, while the average number of circulating shares per person decreased by 20.09% to 13,739 shares [3] - The top ten circulating shareholders include a new entrant, Qianhai Kaiyuan Steady Growth Mixed Fund, holding 1.996 million shares [4] Market Activity - On September 26, JiuZhiTang's stock rose by 2.12%, reaching 10.13 yuan per share, with a trading volume of 1.11 billion yuan and a turnover rate of 1.62% [1] - The net inflow of main funds was 593,400 yuan, with significant buying and selling activity recorded [1]
华人健康跌0.39%,成交额5773.75万元,近5日主力净流入-1320.10万
Xin Lang Cai Jing· 2025-09-25 07:53
Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. is actively expanding its presence in the senior health sector, focusing on chronic disease management and developing products tailored for elderly health needs [2][3]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and went public on March 1, 2023. The company is primarily engaged in pharmaceutical agency, retail, and terminal procurement, with its main revenue derived from traditional Chinese and Western medicine, accounting for 97.60% of total revenue [7]. - As of June 30, 2023, the company had 26,100 shareholders, an increase of 45.15% from the previous period, with an average of 5,725 circulating shares per person, a decrease of 31.10% [8]. Financial Performance - For the first half of 2023, the company achieved a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%. The net profit attributable to shareholders was 104 million yuan, up 42.17% year-on-year [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [8]. Market Position and Shareholder Structure - The company has a market capitalization of 5.132 billion yuan, with a trading volume of 57.7375 million yuan and a turnover rate of 3.00% on September 25, 2023 [1]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company, and there are collaborations with various Alibaba platforms [3]. Strategic Initiatives - The company is focusing on the senior health market by providing chronic disease training and services through pharmacies, enhancing health consultation and medication guidance for the elderly [2]. - It is developing a series of products aimed at common diseases in the elderly, including the "Fuman Medical" series for cardiovascular health and the "Guojin" series of traditional Chinese medicine health products [2][3].
嘉事堂涨2.06%,成交额4951.80万元,主力资金净流入450.95万元
Xin Lang Cai Jing· 2025-09-25 05:56
嘉事堂今年以来股价涨8.94%,近5个交易日涨0.22%,近20日跌1.42%,近60日涨3.43%。 分红方面,嘉事堂A股上市后累计派现8.74亿元。近三年,累计派现2.16亿元。 今年以来嘉事堂已经1次登上龙虎榜,最近一次登上龙虎榜为5月8日,当日龙虎榜净买入-5345.21万 元;买入总计3524.90万元 ,占总成交额比6.51%;卖出总计8870.11万元 ,占总成交额比16.37%。 9月25日,嘉事堂盘中上涨2.06%,截至13:32,报13.89元/股,成交4951.80万元,换手率1.24%,总市值 40.52亿元。 截至9月10日,嘉事堂股东户数2.20万,较上期减少8.40%;人均流通股13248股,较上期增加9.17%。 2025年1月-6月,嘉事堂实现营业收入96.99亿元,同比减少24.45%;归母净利润1.07亿元,同比减少 36.24%。 资金流向方面,主力资金净流入450.95万元,特大单买入480.36万元,占比9.70%,卖出108.23万元,占 比2.19%;大单买入883.12万元,占比17.83%,卖出804.30万元,占比16.24%。 资料显示,嘉事堂药业股份有 ...
一品红跌2.00%,成交额1.84亿元,主力资金净流出1167.36万元
Xin Lang Cai Jing· 2025-09-25 03:00
Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002. The company was listed on November 16, 2017. Its main business involves the research, production, and sales of proprietary drugs, as well as the sales of agency drugs [1][2]. Financial Performance - As of August 31, Yipinhong reported a revenue of 584 million yuan for the first half of 2025, a year-on-year decrease of 36.02%. The net profit attributable to shareholders was -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has cumulatively distributed 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]. Stock Performance - On September 25, Yipinhong's stock price decreased by 2.00%, trading at 58.30 yuan per share, with a total market capitalization of 26.334 billion yuan. The stock has increased by 241.74% year-to-date but has seen a decline of 4.06% in the last five trading days and 11.84% in the last 20 days [1]. - The stock has appeared on the "龙虎榜" (a stock trading list) five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1]. Shareholder Information - As of August 31, the number of shareholders for Yipinhong was 21,400, an increase of 0.49% from the previous period. The average circulating shares per person decreased by 0.49% to 19,553 shares [2]. - As of June 30, 2025, the eighth largest circulating shareholder is E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares as a new shareholder, while Hong Kong Central Clearing Limited has exited the top ten circulating shareholders [3]. Industry Classification - Yipinhong belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical sector, with concepts including anti-influenza, pharmaceutical e-commerce, hepatitis treatment, monkeypox concept, and traditional Chinese medicine [2].
北陆药业涨2.04%,成交额1.08亿元,主力资金净流入244.32万元
Xin Lang Cai Jing· 2025-09-24 06:37
9月24日,北陆药业盘中上涨2.04%,截至14:13,报9.00元/股,成交1.08亿元,换手率2.16%,总市值 50.66亿元。 今年以来北陆药业已经2次登上龙虎榜,最近一次登上龙虎榜为6月17日,当日龙虎榜净买入3375.52万 元;买入总计9540.19万元 ,占总成交额比11.17%;卖出总计6164.67万元 ,占总成交额比7.22%。 资料显示,北京北陆药业股份有限公司位于北京市海淀区西直门北大街32号枫蓝国际写字楼A座7层, 成立日期1992年9月5日,上市日期2009年10月30日,公司主营业务涉及对比剂系列、中枢神经类和降糖 类药品的生产、研发与销售。主营业务收入构成为:对比剂63.33%,中成药22.09%,降糖药12.75%, 其他(补充)1.83%。 北陆药业所属申万行业为:医药生物-化学制药-化学制剂。所属概念板块包括:原料药、医药电商、中 药、基因测序、生物医药等。 截至6月30日,北陆药业股东户数4.39万,较上期增加43.48%;人均流通股11256股,较上期减少 29.84%。2025年1月-6月,北陆药业实现营业收入5.84亿元,同比增长23.27%;归母净利润2996 ...
陇神戎发涨2.10%,成交额4516.86万元,主力资金净流入156.88万元
Xin Lang Cai Jing· 2025-09-24 06:01
9月24日,陇神戎发盘中上涨2.10%,截至13:38,报9.71元/股,成交4516.86万元,换手率1.55%,总市 值29.45亿元。 资金流向方面,主力资金净流入156.88万元,特大单买入100.63万元,占比2.23%,卖出0.00元,占比 0.00%;大单买入842.75万元,占比18.66%,卖出786.50万元,占比17.41%。 陇神戎发所属申万行业为:医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括:甘肃国资、医药电商、中 药、小盘、医疗器械等。 截至9月10日,陇神戎发股东户数2.78万,较上期减少0.71%;人均流通股10853股,较上期增加0.71%。 2025年1月-6月,陇神戎发实现营业收入4.96亿元,同比减少9.91%;归母净利润2795.61万元,同比增长 30.31%。 分红方面,陇神戎发A股上市后累计派现4264.16万元。近三年,累计派现2426.76万元。 机构持仓方面,截止2025年6月30日,陇神戎发十大流通股东中,汇添富中证中药ETF(560080)位居 第六大流通股东,持股97.85万股,相比上期减少10.16万股。 责任编辑:小浪快报 陇神戎发今年以来股价涨1 ...
一品红涨2.02%,成交额2.18亿元,主力资金净流出251.70万元
Xin Lang Cai Jing· 2025-09-24 05:59
Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 252.81%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its listing date on November 16, 2017 [1]. - The company's main business involves the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The revenue composition is as follows: Children's medicine 61.12%, Chronic disease medicine 22.71%, Others 16.17% [1]. Financial Performance - For the first half of 2025, Yipinhong reported operating revenue of 584 million yuan, a year-on-year decrease of 36.02%, and a net profit attributable to shareholders of -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [3]. Shareholder Information - As of August 31, the number of Yipinhong's shareholders was 21,400, an increase of 0.49% from the previous period, with an average of 19,553 circulating shares per person, a decrease of 0.49% [2]. - As of June 30, 2025, Yipinhong's top ten circulating shareholders included E Fund Medical Healthcare Industry Mixed A as the eighth largest shareholder, holding 4.3661 million shares, while Hong Kong Central Clearing Limited exited the top ten list [3]. Market Activity - On September 24, Yipinhong's stock price rose by 2.02% to 60.19 yuan per share, with a trading volume of 218 million yuan and a turnover rate of 0.88%, resulting in a total market capitalization of 27.187 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.5761 million yuan [1].
浙江医药涨2.07%,成交额1.26亿元,主力资金净流入1276.54万元
Xin Lang Zheng Quan· 2025-09-24 05:43
Core Viewpoint - Zhejiang Medicine's stock price has shown a decline of 7.58% year-to-date, with a recent increase of 2.07% on September 24, 2023, indicating potential volatility in the market [1]. Financial Performance - For the first half of 2025, Zhejiang Medicine reported a revenue of 4.323 billion yuan, a year-on-year decrease of 1.87%, while the net profit attributable to shareholders was 673 million yuan, reflecting a significant increase of 113.52% [2]. - Cumulative cash dividends since the company's A-share listing amount to 4.377 billion yuan, with 661 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 65,500, with an average of 14,674 circulating shares per person, a decrease of 0.55% [2]. - The top circulating shareholder, Hong Kong Central Clearing Limited, holds 71.2904 million shares, an increase of 34.9417 million shares compared to the previous period [3].
诚意药业涨2.06%,成交额3814.40万元,主力资金净流入64.81万元
Xin Lang Cai Jing· 2025-09-24 02:31
Core Viewpoint - Chengyi Pharmaceutical's stock price has shown significant volatility, with a year-to-date increase of 78.88% but a recent decline in the last five and twenty trading days [2] Group 1: Stock Performance - As of September 24, Chengyi Pharmaceutical's stock price rose by 2.06% to 13.38 CNY per share, with a market capitalization of 4.379 billion CNY [1] - The stock has experienced a decline of 2.97% over the last five trading days and 5.77% over the last twenty trading days, while it increased by 28.04% over the last sixty days [2] - The company has appeared on the trading leaderboard four times this year, with the most recent instance on August 6, where it recorded a net buy of 138 million CNY [2] Group 2: Financial Performance - For the first half of 2025, Chengyi Pharmaceutical reported a revenue of 417 million CNY, representing a year-on-year growth of 17.11%, and a net profit attributable to shareholders of 112 million CNY, up 47.03% year-on-year [2] - The company has distributed a total of 474 million CNY in dividends since its A-share listing, with 203 million CNY distributed over the past three years [3] Group 3: Business Overview - Chengyi Pharmaceutical, established on June 22, 2001, and listed on March 15, 2017, is primarily engaged in the research, production, and sales of chemical pharmaceutical raw materials and formulations [2] - The revenue composition of the company includes 80.99% from formulations, 17.46% from raw materials, 0.63% from traditional Chinese medicine, and minor contributions from intermediates and food [2] - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including hepatitis treatment and pharmaceutical e-commerce [2]